Cellular interactions in prostate cancer

British Journal of Urology

Volumn 79, Issue SUPPL. 1, 1997, Pages 21-27

  Lee, C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; GROWTH FACTOR;

APOPTOSIS; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; EPITHELIUM CELL; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM;

ANDROGENS; ANIMALS; CELL COMMUNICATION; CELL DIVISION; CYTOKINES; GENES, TUMOR SUPPRESSOR; GROWTH SUBSTANCES; HUMANS; MALE; MICE; MUTATION; ONCOGENES; PROSTATIC NEOPLASMS;

EID: 0031397717     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410x.1997.tb00797.x     Document Type: Article

References (47)

1. Aaronson S. Growth factors and cancer. Science 1991; 254: 1146-53
2. Bruchovsky N, Lesser B, van Doom E, Craven S. Hormonal effects on cell proliferation in rat prostate. Vit Harm 1975; 33: 61-102
3. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1985; 5: 545-57
4. Lee C. Physiology of castration-induced regression in rat prostate. In Murphy G, Sandberg AA, Karr JP, eds, The Prostate Cell: Structure and Function. New York: Alan R. Liss, 1981: 231-46
5. Lee C. Role of androgen in prostate growth and regression: Stromal-epithelial interaction. Prostate 1996: 6 (Suppl.): 52-6
6. Lee C, Kozlowski JM, Grayhack JT. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 1997. in press
7. Volgelstein B, Fearon ER, Hamilton SR et al. Genetic alternations during colonrectal-tumor development. N Engl J Medl988: 319: 525-32
8. Kozlowski JM, Grayhack JT. Carcinoma of the prostate. In Gillenwater J, Grayhack JT, Howards S, Duckett J, eds, Adult and Pediatrie Urology. Chicago: Yearbook, 1991: 1277-393
9. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the newborn animal. J Biol Chem 1962; 237: 1555-62
10. Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol 1965; 12: 394-407
11. Hiramatsu M, Kashimata M, Minami N, Sato A, Muragama M, Minami N. Androgenic regulation of EGF in the mouse ventral prostate. Biochem Int 1988: 17: 311-17
12. Hofer D, Sherwood E, Bromberg W, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgenindependent prostatic carcinoma cells: Role of TGF-α. Cancer Res 1991; 51: 2780-5
13. Kyprianou N. Isaacs JT. Expression of transforming growth factor-β in the rat ventral prostate during castrationinduced programmed cell death. Mol Endocrinol 1989; 3: 1515-22
14. Martikainene P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells. Endocrinology 1990; 127: 2963-8
15. Peehl DM, Cohen P, Rosenfeld RG. The insulin-like growth factor system in the prostate. World J Urol 1996; 13: 306-11
16. Sherwood ER, Fong CJ, Lee C, Kozlowski JM. Basic fibroblast growth factor: A potential mediator of stromal growth in the human prostate. Endocrinology 1992; 130: 2955-63
17. Story M. Regulation of prostate growth by fibroblast growth factors. World J Urol 1996; 13: 297-305
18. Djakiew D. Role of nerve growth factor-like protein in the paracrine regulation of prostate growth. J Androl 1992; 13: 476-87
19. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1996, 57: 141-6
20. McNeal J. Normal histology of the prostate. Am J Surg Pathol 1988; 12: 619-33
21. Yan G, Fukabori Y, Nikolaropoulou S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 1992; 6: 2123-8
22. Peehl DM, Rubin JS. Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interaction in the prostate. World] Urol 1996: 13: 312-17
23. Sugimura Y, Cunha GR, Hay ward S et al. Keratinocyte growth factor (KGF) is a mediator of testosterone-induced prostatic development. Mol Cell Differ 1993; 1: 423
24. Nemeth JA, Sensibar JA, Lee C. Changes in TGF-β localisation in the rat prostatic ductal system during castration-induced regression. Presented at the 77th Annual Meeting for the Endocrine Society, Washington, D.C., 14-17 June 1995 (Abst# PI-361)
25. Kim IY, Ahn HJ, Zelner DJ, Park L, Sensibar JA, Lee C. Expression and localisation of transforming growth factor-β receptors type I and type in the rat ventral prostate during regression. Mol Endocrinol 1996; 10: 107-15
26. Lee C, Sutkowski DM, Sensibar JA et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells. LNCaP, by dihydrotestosterone. Endocrinology 1995; 136: 796-803
27. Horoszewicz JS, Leong SS, Kawinski E et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-17
28. Young CYE, Montgomery BT, Andrews PE, Qiu S, Bilhartz BL, Tindal DJ. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991; 53: 3748-52
29. Wilding G, Chen M, Gelman E. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14: 103-15
30. Veldscholte J, Ris-Staplers C, Kuiper GGJM et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173: 534-40
31. Kokontis J, Kiyoshi I, Hiipakka RA, Liao S. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Receptor 1991; 1: 271-9
32. Sonnenschein C, Olea N, Fasanen ME, Soto AM. Negative controls of cell proliferation: human prostate cancers and androgens. Cancer Res 1989; 49: 3474-81
33. Kassen A, Kozlowski JM, Lee C. Role of basic fibroblast growth factor in the autocrine regulation of LNCaP proliferation induced by dihydrotestosterone. 77th Annual Meeting for the Endocrine society, Washington, D.C., 14-17 June 1995 (Abst# PI-639)
34. Kirn IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar JA, Lee C. Transforming growth factor-β1 is a mediator of androgenregulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996; 137: 991-9
35. Cross M, Dexter TM. Growth factors in development, transformation and tumorigenesis. Cell 1991; 64: 271-80
36. Kozlowski JM, Fidler IJ, Campbell D, Zu ZL, Kaighn ME, Hart IR. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984; 44: 3522-9
37. Lee C, Shevrin DH, Kozlowski JM. In vivo and in vitro approaches to study metastasis in human prostatic cancer. Cancer Metast Rev 1993; 12: 21-8
38. Fong CJ, Sherwood ER, Mendelsohn J, Lee C, Kozlowski JM. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitises androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res 1993; 52: 5887-92
39. Sherwood ER, Lee C. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 1995; 13: 290-6
40. Siegall CB, Schwab G, Nordan RP, FitzGerald DJ. Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990; 50: 7785-8
41. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kirn WY, Simons JW. Interleukin-6: A candidate mediator of human prostate cancer mobidity. Urology 1994; 45: 542-9
42. Weinberg R. Tumor suppressor genes. Science 1991: 254: 1138-46
43. Roberts AB, Sporn MD, Assoian RK et al. Transforming growth factor type-b. Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sei USA 1986; 83: 4167-71
44. Wilding G. Response to prostate cancer cells to peptide growth factors: Transforming growth factor-β. Cancer Surv 1991; 11: 147-63
45. Steiner M, Barrack ER. Transforming growth factor-β overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endochnol 1992; 6: 15-25
46. Thompson TC, Truong ID, Timme TL et al. Transgenic models for the study of prostate cancer. Cancer 1993; 71: 1165-71
47. Wrana JL, Attisano L, Wiesser R, Ventura F. Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994: 370: 341-7